NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
Rhea-AI Summary
NKGen Biotech (OTC: NKGN) reported pooled Phase 1 troculeucel data presented at AD/PD 2026 showing dose‑responsive cognitive improvements and biomarker correlations in Alzheimer’s disease. In moderate AD patients (n=6) 100% were stable or improved at three months and 50% improved from moderate to mild on CDR‑SB.
Exploratory plasma GFAP correlated with clinical measures (r up to 0.76, p≤0.009) and higher doses (4–6B cells) showed stronger associations; two patients had maintained benefit through 12 months. No treatment‑related adverse events were reported.
Positive
- 100% of moderate AD patients stable or improved at three months (n=6)
- 50% improved from moderate to mild on CDR‑SB at three months
- Dose‑responsive effects: higher doses (4–6B cells) linked to greater clinical benefit
- Plasma GFAP showed strong correlations with cognition (e.g., r=0.76, p=0.009)
- Favorable safety: no treatment‑related adverse events reported across Phase 1
Negative
- Small moderate‑stage sample size (n=6) limits statistical power and generalizability
- Durability data limited: only 2 patients had 12‑month follow‑up on therapy
- Open‑label Phase 1 design lacks randomized, controlled comparison for efficacy assessment
Key Figures
Market Reality Check
Peers on Argus
NKGN was down 6.25% while key peers were mostly flat; only TELIF moved, down 0.79%, pointing to a stock-specific reaction rather than a broad biotech move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jul 28 | Phase 1 data update | Positive | +0.0% | AAIC 2025 Phase 1 data showing 92% stable or improved cognition and biomarker effects. |
| Jun 23 | Trial expansion | Positive | -11.0% | International and U.S. expansion of Phase 1/2a Alzheimer’s trial with new sites activated. |
| Apr 07 | AD/PD 2025 data | Positive | -27.8% | AD/PD™ 2025 update showing high-dose 6B cell cohort with moderate-to-mild improvements and biomarker gains. |
| Feb 13 | Phase 1 publication | Positive | -8.7% | Peer-reviewed Phase 1 publication reporting 90% stable or improved subjects and dose-dependent biomarker changes. |
| Oct 29 | CTAD data | Positive | -11.2% | CTAD presentation of Phase 1/2a data with 6B-cell dosing and moderate-to-mild cognitive improvements. |
Clinical trial updates for troculeucel have consistently been positive, yet the stock has tended to trade flat or down on these releases, suggesting a pattern of weak price alignment with favorable data.
Over the past year, NKGen has repeatedly reported encouraging Phase 1 and Phase 1/2a troculeucel data in Alzheimer’s disease, including biomarker reductions and dose‑dependent cognitive benefits on Oct 29, 2024, Feb 13, 2025, Apr 7, 2025, and Jul 28, 2025. Despite these advances and trial expansion on Jun 23, 2025, 24‑hour price moves around such clinical updates were neutral to negative. Today’s AD/PD™ 2026 pooled Phase 1 analysis extends this data continuum with more moderate-stage detail.
Historical Comparison
In the last 5 clinical-trial releases, NKGN moved on average -11.72%. Today’s -6.25% reaction to new Phase 1 Alzheimer’s data remains negative but is less severe than prior same-tag moves.
Clinical communications have progressed from early Phase 1 biomarker and safety readouts to more detailed, dose-responsive cognitive data in moderate Alzheimer’s and support for an ongoing Phase 2 program.
Market Pulse Summary
This announcement adds to a growing body of Phase 1 evidence that troculeucel produced dose‑responsive, durable cognitive stability or improvement in moderate Alzheimer’s disease, alongside strong plasma GFAP correlations with clinical status. Combined with prior conference and publication data, it reinforces biological activity and safety as the Phase 2 trial proceeds. Investors may focus on upcoming randomized data, enrollment progress, and how future results intersect with the company’s financial constraints disclosed in recent SEC filings.
Key Terms
phase 1 medical
phase 2 medical
glial fibrillary acidic protein medical
biomarker medical
open-label medical
AI-generated analysis. Not financial advice.
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability.
Exploratory plasma GFAP correlations are consistent with observed clinical outcomes.
Findings support further evaluation of troculeucel’s immunomodulatory approach in the ongoing Phase 2 trial.
SANTA ANA, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced new data presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (“AD/PD™ 2026”), held March 17-21, 2026, in Copenhagen, Denmark and virtually.
NKGen’s combined Phase 1 analyses from two previously completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease (AD) demonstrated encouraging signs of biological activity, with
“As most of the attention has focused on treating the Mild Cognitive Impairment (MCI) Alzheimer’s population, we wanted to focus on the moderate stage disease population for which there is no effective disease modifying therapy. Despite the rapid rate of cognitive decline typically seen in moderate stage patients, we were able to stop or improve cognitive decline in
Oral Presentation Shows Encouraging Dose‑Responsive Cognitive Activity and Maintenance of Benefit with Troculeucel in Moderate Alzheimer’s Disease
Pooled analysis of two previously reported open‑label Phase 1 studies (NCT04678453; NCT06189963) evaluating troculeucel in moderate AD showed encouraging and consistent signs of biological activity across dose levels ranging from 1 to 6 billion cells. At the three‑month assessment, all patients showed stability or improvement across multiple standardized cognitive measures, with higher doses associated with greater directional benefit and more frequent achievement of clinically meaningful change. Early durability signals were also observed in those patients followed for up to 12 months, and troculeucel continued to demonstrate a favorable safety profile with no treatment‑related adverse events reported.
Cognitive Outcomes (3‑Month Assessment; n=6 moderate AD patients)
100% of patients were stable or improved across all established minimal clinically important difference (MCID) thresholds:- Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; ± 4 points)
- Clinical Dementia Rating-Sum of Boxes (CDR-SB; ± 2 points)
- Alzheimer’s Disease Composite Score (ADCOMS; ± 0.1 points)
- No cognitive decline was observed in any patient.
- Higher doses (4–6B cells) were associated with greater directional improvement and more frequent MCID exceedance.
50% of patients improved from the moderate to mild range on CDR‑SB at three months.
Durability (Up to 12 Months)
- In the two patients remaining on therapy for 12 months, improvements across cognitive measures were maintained throughout treatment, suggesting early durability of effect.
Safety
- Troculeucel was very well‑tolerated, with no treatment‑related adverse events reported across both Phase 1 studies.
Poster Presentation Highlights Strong and Consistent Plasma GFAP Correlations Supporting Its Potential as a Non‑Invasive Biomarker of Clinical Status in Alzheimer’s Disease
In a separate poster presentation, NKGen reported exploratory plasma GFAP analyses from all AD patients treated across the two Phase 1 studies described above, demonstrating strong and consistent correlations between GFAP levels and established clinical measures of disease severity. These findings were observed at baseline, maintained following troculeucel treatment, and further strengthened in patients receiving higher cell doses, reinforcing the potential of plasma GFAP as a reliable, non-invasive biomarker of neuroinflammation and clinical status. The consistency of these correlations across timepoints and dose levels provides important translational support as NKGen advances troculeucel’s clinical development.
Data summary:
- Plasma GFAP demonstrated strong and statistically significant correlations with cognitive status at baseline, supporting its role as a biomarker of disease severity in Alzheimer’s disease.
- Baseline plasma GFAP levels correlated with CDR-SB (r=0.60, p=0.044) and ADCOMS (r=0.64, p=0.030)
- GFAP–cognition correlations remained robust following troculeucel treatment
- After three months of therapy, plasma GFAP continued to correlate with CDR-SB (r=0.57, p=0.056) and ADCOMS (r=0.66, p=0.022), demonstrating consistency of biomarker–clinical relationships over time
- In moderate AD patients receiving ≥4 billion cells (n=4), correlations strengthened further, with statistically significant associations observed across timepoints for CDR-SB (r=0.76, p=0.009) and ADCOMS (r=0.71, p=0.018)
- Pooled longitudinal analyses across disease severities and timepoints reinforced the reliability of plasma GFAP as a clinical-status biomarker, with strong correlations observed for CDR-SB (r=0.56, p=0.001) and ADCOMS (r=0.50, p=0.004)
- These findings support the continued evaluation of plasma GFAP as a non-invasive biomarker of neuroinflammation and clinical status in Alzheimer’s disease.
A copy of the presentations will be made available on the Company’s website under the Scientific Publications section, once the event has concluded. Additionally, previously disclosed scientific data on troculeucel for neurodegenerative disease can be accessed on the same page. For the latest updates on our clinical trials and regulatory announcements, please visit the Company’s News page. Note that results reported are from the completed Phase 1 trials and do not include results from the Company’s ongoing Phase 2 trial, which is actively enrolling.
About Troculeucel
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public disclosures; the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company’s acquisition of a majority interest in NKGen Biotech Korea Co., Ltd., including risks regarding the future performance of NKGen Biotech Korea Co., Ltd.’s business, the Company’s ability to successfully integrate NKGen Biotech Korea Co., Ltd.’s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the SEC’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contacts:
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
1 GFAP is a structural protein released by activated astrocytes and serves as a widely recognized blood-based biomarker of neuroinflammation in Alzheimer’s disease, with elevated plasma or CSF levels consistently associated with greater disease severity, faster progression, and more extensive amyloid-related pathology.
FAQ
What did NKGen (NKGN) report at AD/PD 2026 about troculeucel efficacy in moderate Alzheimer’s disease on March 23, 2026?
How strong were the plasma GFAP correlations with cognition reported by NKGen (NKGN) at AD/PD 2026?
What safety profile did NKGen (NKGN) report for troculeucel in the pooled Phase 1 Alzheimer’s studies?
What are the limitations of NKGen’s (NKGN) Phase 1 troculeucel data presented at AD/PD 2026?
Does NKGen (NKGN) report durability of troculeucel effects beyond three months at AD/PD 2026?
How will the AD/PD 2026 findings affect NKGen’s (NKGN) clinical development of troculeucel?
